Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immunohistochemical stainings were performed to observe the expression of the blood group antigens (A, B, H, Lewisa, Lewisb) and lactoseries type 1 core chain in normal and neoplastic endometrial tissues using a panel of monoclonal antibodies. The results indicated that normal endometrium mostly lacked the expression of these sugar structures. In endometrial carcinoma, the expression of H, Lewisa, Lewisb was evident and type 1 core chain was observed only after neuraminidase pretreatment. These data indicated that type 1 core chains were newly synthesized according to malignant transformations in endometrial tissues and they were partially fucosylated and partially sialylated.
 ...
PMID:Immunohistochemical localization of blood group substances in normal and neoplastic endometrial tissues--with special reference to type 1 core chain expression. 175 1

A human monoclonal antibody termed HMST-1 was produced by fusing lymphocytes from segments of human pelvic lymph nodes from an endometrial cancer patient with murine myeloma cells. The epitope recognized by HMST-1 was determined to be lacto-series type 1 chain-containing glycosphingolipid (Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer) by isolating the antigen from endometrial cancer cell line SNG-II and analyzing with fast atom bombardment mass spectrometry, permethylation analysis, and exoglycosidase treatment. By the immunohistochemical avidin-biotin-peroxidase complex method, no normal endometrium and benign endometrial hyperplasia were stained with HMST-1, but HMST-1 reacted with about 35% of endometrial cancer cases. These facts indicate that the rate of expression of the antigen increases along with the course of malignancy in the endometrium. By sialidase treatment of the section, the positive rate increased to 57% in endometrial cancers and to 13% in normal endometrium, indicating that the antigen was masked with sialic acid and exposed by neuraminidase treatment. Immunohistochemistry also revealed that the antibody reacted with human fetal alimentary tract epithelium and mesothelium, indicating the oncodevelopmental nature of Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer.
 ...
PMID:Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers. 268 63

A murine monoclonal antibody, 1C5, was produced by fusion of spleen cells obtained from mice immunized with CAC-1, a human cell line of adenocarcinoma derived from uterine cervix, and NS/1 myeloma cells. 1C5 can be used for the staining of routine formalin-fixed and paraffin-embedded tissue sections. 1C5-defined antigen was found to have a molecular weight of 26,000. The 1C5-defined antigen was resistant to neuraminidase and trypsin treatment, but sensitive to periodate treatment, indicating that an epitope of the 1C5-defined antigen is a carbohydrate moiety. Immunohistochemical study using immunoperoxidase staining demonstrated that 1C5 reacted with 87% of adenocarcinomas of the uterine cervix, 39% of endometrial carcinomas of the uterus, 100% of ovarian mucinous cystadenocarcinomas, 43% of ovarian serous cystadenocarcinomas, 45% of adenocarcinomas of the colon, and 40% of gastric adenocarcinomas, thus showing the broad reactivity to adenocarcinoma cells of various origins. However, 1C5 did not show any reactivity to ectocervix epithelium, cervical intraepithelial neoplasia, or squamous cell carcinoma of the uterine cervix. In addition, adenocarcinoma of the uterine cervix exhibited strong cytoplasmic reactivity with 1C5, whereas endometrial carcinoma of the uterus showed the luminal reactivity. 1C5 also reacts with 95% ethanol-fixed malignant cells in cervical smears.
 ...
PMID:New monoclonal antibody, 1C5, reactive with human cervical adenocarcinoma of the uterus, with immunodiagnostic potential. 305 7

The binding of Ulex europeus agglutinin-I (UEA-I) and Peanut agglutinin (PNA) was studied in 56 endometrial carcinomas. The positive rates of UEA-I and PNA were 66%. Following neuraminidase treatment, the PNA positive rate increased from 66% to 98% and most tumors stained abundantly. UEA-I staining was unaffected. Using a combined grading system based on architectural and nuclear abnormalities, the PNA positive rates of grade 1, grade 2 and grade 3 tumors were 78%, 70% and 36%, respectively. There was no correlation between UEA-I binding and the grading systems. UEA-I binding correlated significantly with the presence of myometrial invasion and vessel permeation. Metastatic endometrial carcinomas showed a high affinity of tumor cells for UEA-I. Tissues that stained with UEA-I were those from patients with the worst prognosis. PNA and UEA-I reactivities relate to the biologic activity of endometrial carcinomas. UEA-I can serve as a prognostic marker for patients with endometrial carcinoma.
 ...
PMID:Assessment of lectin binding for prognosis in endometrial carcinoma. 799 Dec 74